FDA introduces orphan drug pilot scheme
JHVEphoto / Shutterstock.com
The US Court of Appeals for the Eleventh Circuit has found that the US Food and Drug Administration (FDA) violated the exclusivity of a patent covering a drug for a rare autoimmune disorder, by approving the same treatment specifically for children.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Catalyst Pharmaceuticals, Food and Drug Administration, US Court of Appeals for the Eleventh Circuit, autoimmune, orphan drugs, Jacobus Pharmaceuticals